logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12269873 B1

PDFFull Text
Date of Patent:
Apr. 08, 2025

Filed:

Mar. 22, 2022

Signature of tl1a (tnfsf15) signaling pathway

Applicant:

Cedars-sinai Medical Center, Los Angeles, CA (US);

Inventors:

Kathrin S. Michelsen, Los Angeles, CA (US);

Stephan R. Targan, Santa Monica, CA (US);

Assignee:

CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US);

Attorney:

Wilson Sonsini Goodrich & Rosati

Primary Examiner:

Bridget E Bunner

Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/24 (2006.01); C12Q 1/68 (2018.01); C12Q 1/6827 (2018.01); C12Q 1/6883 (2018.01); G01N 33/483 (2006.01); G01N 33/50 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01); C07K 14/425 (2006.01); C07K 14/54 (2006.01); G01N 15/149 (2024.01); G01N 33/569 (2006.01);
U.S. Cl.
CPC ...
C07K 16/241 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/244 (2013.01); C12Q 1/68 (2013.01); C12Q 1/6883 (2013.01); G01N 33/483 (2013.01); G01N 33/50 (2013.01); G01N 33/53 (2013.01); G01N 33/68 (2013.01); G01N 33/6863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 15/149 (2024.01); G01N 33/56966 (2013.01); G01N 2333/5425 (2013.01); G01N 2333/70575 (2013.01); G01N 2800/065 (2013.01); G01N 2800/12 (2013.01); G01N 2800/24 (2013.01); G01N 2800/7095 (2013.01);
Abstract

The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.

Find Patent Forward Citations

Michelsen, Kathrin. (2025). Signature of tl1a (tnfsf15) signaling pathway (U.S. Patent No. 12269873). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12269873

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…